The Acne Family 331
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Proper Preop Makes for Easier Toenail Surgery
April 15, 2007 • www.familypracticenews.com Skin Disorders 25 Proper Preop Makes for Easier Toenail Surgery BY JEFF EVANS sia using a digital block or a distal approach to take ef- Senior Writer fect. Premedication with NSAIDs, codeine, or dextro- propoxyphene also may be appropriate, he said. WASHINGTON — Proper early management of in- To cut away the offending section of nail, an English grown toenails may help to decrease the risk of recur- anvil nail splitter is inserted under the nail plate and the rence whether or not surgery is necessary, Dr. C. Ralph cut is made all the way to the proximal nail fold. The hy- Daniel III said at the annual meeting of the American pertrophic, granulated tissue should be cut away as well. Academy of Dermatology. Many ingrown toenails are recurrent, so Dr. Daniel per- “An ingrown nail is primarily acting as a foreign-body forms a chemical matricectomy in nearly all patients after reaction. That rigid spicule penetrates soft surrounding tis- making sure that the surgical field is dry and bloodless. sue” and produces swelling, granulation tissue, and some- The proximal nail fold can be flared back to expose more times a secondary infection, said Dr. Daniel of the de- of the proximal matrix if necessary. Dr. Daniel inserts a Cal- partments of dermatology at the University of Mississippi, giswab coated with 88% phenol or 10% sodium hydroxide Jackson, and the University of Alabama, Birmingham. and applies the chemical for 30 seconds to the portion of For the early management of stage I ingrown toenails the nail matrix that needs to be destroyed. -
Oral Lichen Planus: a Case Report and Review of Literature
Journal of the American Osteopathic College of Dermatology Volume 10, Number 1 SPONSORS: ',/"!,0!4(/,/'9,!"/2!4/29s-%$)#)3 March 2008 34)%&%,,!"/2!4/2)%3s#/,,!'%.%8 www.aocd.org Journal of the American Osteopathic College of Dermatology 2007-2008 Officers President: Jay Gottlieb, DO President Elect: Donald Tillman, DO Journal of the First Vice President: Marc Epstein, DO Second Vice President: Leslie Kramer, DO Third Vice President: Bradley Glick, DO American Secretary-Treasurer: Jere Mammino, DO (2007-2010) Immediate Past President: Bill Way, DO Trustees: James Towry, DO (2006-2008) Osteopathic Mark Kuriata, DO (2007-2010) Karen Neubauer, DO (2006-2008) College of David Grice, DO (2007-2010) Dermatology Sponsors: Global Pathology Laboratory Stiefel Laboratories Editors +BZ4(PUUMJFC %0 '0$00 Medicis 4UBOMFZ&4LPQJU %0 '"0$% CollaGenex +BNFT2%FM3PTTP %0 '"0$% Editorial Review Board 3POBME.JMMFS %0 JAOCD &VHFOF$POUF %0 Founding Sponsor &WBOHFMPT1PVMPT .% A0$%t&*MMJOPJTt,JSLTWJMMF .0 4UFQIFO1VSDFMM %0 t'"9 %BSSFM3JHFM .% wwwBPDEPSg 3PCFSU4DIXBS[F %0 COPYRIGHT AND PERMISSION: written permission must "OESFX)BOMZ .% be obtained from the Journal of the American Osteopathic College of Dermatology for copying or reprinting text of .JDIBFM4DPUU %0 more than half page, tables or figurFT Permissions are $JOEZ)PGGNBO %0 normally granted contingent upon similar permission from $IBSMFT)VHIFT %0 the author(s), inclusion of acknowledgement of the original source, and a payment of per page, table or figure of #JMM8BZ %0 reproduced matFSJBMPermission fees -
Fungal Infections from Human and Animal Contact
Journal of Patient-Centered Research and Reviews Volume 4 Issue 2 Article 4 4-25-2017 Fungal Infections From Human and Animal Contact Dennis J. Baumgardner Follow this and additional works at: https://aurora.org/jpcrr Part of the Bacterial Infections and Mycoses Commons, Infectious Disease Commons, and the Skin and Connective Tissue Diseases Commons Recommended Citation Baumgardner DJ. Fungal infections from human and animal contact. J Patient Cent Res Rev. 2017;4:78-89. doi: 10.17294/2330-0698.1418 Published quarterly by Midwest-based health system Advocate Aurora Health and indexed in PubMed Central, the Journal of Patient-Centered Research and Reviews (JPCRR) is an open access, peer-reviewed medical journal focused on disseminating scholarly works devoted to improving patient-centered care practices, health outcomes, and the patient experience. REVIEW Fungal Infections From Human and Animal Contact Dennis J. Baumgardner, MD Aurora University of Wisconsin Medical Group, Aurora Health Care, Milwaukee, WI; Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI; Center for Urban Population Health, Milwaukee, WI Abstract Fungal infections in humans resulting from human or animal contact are relatively uncommon, but they include a significant proportion of dermatophyte infections. Some of the most commonly encountered diseases of the integument are dermatomycoses. Human or animal contact may be the source of all types of tinea infections, occasional candidal infections, and some other types of superficial or deep fungal infections. This narrative review focuses on the epidemiology, clinical features, diagnosis and treatment of anthropophilic dermatophyte infections primarily found in North America. -
Communicable Disease Exclusion Guidelines for Schools and Child Care Settings
Deschutes County Health Services COMMUNICABLE DISEASE EXCLUSION GUIDELINES FOR SCHOOLS AND CHILD CARE SETTINGS Symptoms requiring exclusion of a child from school or childcare setting until either diagnosed and cleared by a licensed health care provider or recovery. FEVER: ANY fever greater than 100.5 F., may return when temperature decreases without use of fever-reducing medicine. VOMITTING: > 2 in the preceding 24 hours, unless determined to be from non-communicable conditions. May return when resolved. DIARRHEA: 3 or more watery or loose stools in 24 hours. May return when resolved for 24 hours. STIFF NECK: or headache with accompanying fever. May return after resolution of symptoms or diagnosis made and clearance given. RASHES: ANY new onset of rash if accompanied by fever; may return after rash resolves or if clearance given by health care providers. SKIN LESIONS: Drainage that cannot be contained within a bandage. JAUNDICE: Yellowing of eyes or skin. May return after diagnosis from physician and clearance given. BEHAVIOR CHANGE: Such as new onset of irritability, lethargy or somnolence. COUGH /SOB: Persistent cough with or without fever, serious sustained coughing, shortness of breath, or difficulty breathing. SYMPTOMS or complaints that prevent the student from active participation in usual school activities, or student requiring more care than the school staff can safely provide. Inform local county health department, (LHD), of all diseases listed as reportable. The local county health department should be consulted regarding any written communication that may be developed to inform parents/guardians about disease outbreaks, risk to students, families, and staff and/or control measures specific to an outbreak. -
Pediatric and Adolescent Dermatology
Pediatric and adolescent dermatology Management and referral guidelines ICD-10 guide • Acne: L70.0 acne vulgaris; L70.1 acne conglobata; • Molluscum contagiosum: B08.1 L70.4 infantile acne; L70.5 acne excoriae; L70.8 • Nevi (moles): Start with D22 and rest depends other acne; or L70.9 acne unspecified on site • Alopecia areata: L63 alopecia; L63.0 alopecia • Onychomycosis (nail fungus): B35.1 (capitis) totalis; L63.1 alopecia universalis; L63.8 other alopecia areata; or L63.9 alopecia areata • Psoriasis: L40.0 plaque; L40.1 generalized unspecified pustular psoriasis; L40.3 palmoplantar pustulosis; L40.4 guttate; L40.54 psoriatic juvenile • Atopic dermatitis (eczema): L20.82 flexural; arthropathy; L40.8 other psoriasis; or L40.9 L20.83 infantile; L20.89 other atopic dermatitis; or psoriasis unspecified L20.9 atopic dermatitis unspecified • Scabies: B86 • Hemangioma of infancy: D18 hemangioma and lymphangioma any site; D18.0 hemangioma; • Seborrheic dermatitis: L21.0 capitis; L21.1 infantile; D18.00 hemangioma unspecified site; D18.01 L21.8 other seborrheic dermatitis; or L21.9 hemangioma of skin and subcutaneous tissue; seborrheic dermatitis unspecified D18.02 hemangioma of intracranial structures; • Tinea capitis: B35.0 D18.03 hemangioma of intraabdominal structures; or D18.09 hemangioma of other sites • Tinea versicolor: B36.0 • Hyperhidrosis: R61 generalized hyperhidrosis; • Vitiligo: L80 L74.5 focal hyperhidrosis; L74.51 primary focal • Warts: B07.0 verruca plantaris; B07.8 verruca hyperhidrosis, rest depends on site; L74.52 vulgaris (common warts); B07.9 viral wart secondary focal hyperhidrosis unspecified; or A63.0 anogenital warts • Keratosis pilaris: L85.8 other specified epidermal thickening 1 Acne Treatment basics • Tretinoin 0.025% or 0.05% cream • Education: Medications often take weeks to work AND and the patient’s skin may get “worse” (dry and red) • Clindamycin-benzoyl peroxide 1%-5% gel in the before it gets better. -
(CD-P-PH/PHO) Report Classification/Justifica
COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities. -
Aars Hot Topics Member Newsletter
AARS HOT TOPICS MEMBER NEWSLETTER American Acne and Rosacea Society 201 Claremont Avenue • Montclair, NJ 07042 (888) 744-DERM (3376) • [email protected] www.acneandrosacea.org Like Our YouTube Page We encourage you to TABLE OF CONTENTS invite your colleagues and patients to get active in AARS in the Community the American Acne & Don’t forget to attend the 14th Annual AARS Networking Reception tonight! ........... 2 Rosacea Society! Visit Our first round of AARS Patient Videos are being finalized now ............................... 2 www.acneandrosacea.org Save the Date for the 8th Annual AARS Scientific Symposium at SID ..................... 2 to become member and Please use the discount code AARS15 for 15% off of registration to SCALE ........... 2 donate now on www.acneandrosacea.org/ Industry News donate to continue to see Ortho Dermatologics launches first cash-pay prescription program in dermatology . 2 a change in acne and Cutera to unveil excel V+ next generation laser platform at AAD Annual Meeting ... 3 rosacea. TARGET PharmaSolutions launches real-world study .............................................. 3 New Medical Research Epidemiology and dermatological comorbidity of seborrhoeic dermatitis ................... 4 A novel moisturizer with high SPF improves cutaneous barrier function .................... 5 Randomized phase 3 evaluation of trifarotene 50 μG/G cream treatment ................. 5 Open-label, investigator-initiated, single site exploratory trial..................................... 6 Erythematotelangiectatic -
WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA). -
Isotretinoin Induced Periungal Pyogenic Granuloma Resolution with Combination Therapy Jonathan G
Isotretinoin Induced Periungal Pyogenic Granuloma Resolution with Combination Therapy Jonathan G. Bellew, DO, PGY3; Chad Taylor, DO; Jaldeep Daulat, DO; Vernon T. Mackey, DO Advanced Desert Dermatology & Mohave Centers for Dermatology and Plastic Surgery, Peoria, AZ & Las Vegas, NV Abstract Management & Clinical Course Discussion Conclusion Pyogenic granulomas are vascular hyperplasias presenting At the time of the periungal eruption on the distal fingernails, Excess granulation tissue and pyogenic granulomas have It has been reported that the resolution of excess as red papules, polyps, or nodules on the gingiva, fingers, the patient was undergoing isotretinoin therapy for severe been described in both previous acne scars and periungal granulation tissue secondary to systemic retinoid therapy lips, face and tongue of children and young adults. Most nodulocystic acne with significant scarring. He was in his locations.4 Literature review illustrates rare reports of this occurs on withdrawal of isotretinoin.7 Unfortunately for our commonly they are associated with trauma, but systemic fifth month of isotretinoin therapy with a cumulative dose of adverse event. In addition, the mechanism by which patient, discontinuation of isotretinoin and prevention of retinoids have rarely been implicated as a causative factor 140 mg/kg. He began isotretinoin therapy at a dose of 40 retinoids cause excess granulation tissue of the skin is not secondary infection in areas of excess granulation tissue in their appearance. mg daily (0.52 mg/kg/day) for the first month and his dose well known. According to the available literature, a course was insufficient in resolving these lesions. To date, there is We present a case of eruptive pyogenic granulomas of the later increased to 80 mg daily (1.04 mg/kg/day). -
C&P Service Clinician's Guide
C&P Service Clinician’s Guide CLINICIAN’S GUIDE MARCH 2002 1 C&P Service Clinician’s Guide Table of Contents Table of Contents 2 PREFACE 4 Chapter 1 – INTRODUCTION TO COMPENSATION AND PENSION 5 Worksheet – Aid and Attendance or Housebound Examination 16 Worksheet – General Medical Examination 18 Chapter 2 – DISEASES OF THE SKIN INCLUDING SCARS 22 Worksheet – Skin Diseases (Other Than Scars) 28 Worksheet – Scars 29 Chapter 3 – BIRTH DEFECTS IN CHILDREN OF VIETNAM VETERANS 30 SECTION I: Children with spina bifida who are the children of Vietnam veterans 30 SECTION II: Children with birth defects who are the children of women Vietnam veterans 32 Chapter 4 – EYE 34 Worksheet – Eye Examination 39 Chapter 5 – EAR, MOUTH, NOSE AND THROAT 42 Worksheet – Audio 57 Worksheet – Dental and Oral 59 Worksheet – Ear Disease 60 Worksheet – Mouth, Lips and Tongue 62 Worksheet – Nose, Sinus, Larynx, and Pharynx 63 Worksheet – Sense of Smell and Taste 64 Chapter 6 – RESPIRATORY 65 Worksheet – Respiratory (Obstructive, Restrictive, and Interstitial) 71 Worksheet – Respiratory Diseases, Miscellaneous 73 Worksheet – Pulmonary Tuberculosis and Mycobacterial Diseases 75 Chapter 7 – CARDIOVASCULAR SYSTEM 77 Worksheet – Arrhythmias 88 Worksheet – Arteries, Veins, and Miscellaneous 90 Worksheet – Heart 93 Worksheet – Hypertension 95 1 C&P Service Clinician’s Guide Chapter 8 – DISEASES OF THE DIGESTIVE SYSTEM 96 SECTION I: ESOPHAGUS 96 SECTION II: STOMACH 101 SECTION III: INTESTINE 103 SECTION IV: RECTUM AND ANUS 107 SECTION V: ALIMENTARY APPENDAGES 110 Worksheet -
Skin Conditions and Related Need for Medical Care Among Persons 1=74 Years United States, 1971-1974
Data from the Series 11 NATIONAL HEALTH SURVEY Number 212 Skin Conditions and Related Need for Medical Care Among Persons 1=74 Years United States, 1971-1974 DHEW Publication No. (PHS) 79-1660 U.S, DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service Office of the Assistant Secretary for Health National Center for Health Statistics Hyattsville, Md. November 1978 NATIONAL CENTIER FOR HEALTH STATISTICS DOROTHY P. RICE, Director ROBERT A. ISRAEL, Deputy Director JACOB J. FELDAMN, Ph.D., Associate Director for Amdy.sis GAIL F. FISHER, Ph.D., Associate Director for the Cooperative Health Statistics System ELIJAH L. WHITE, Associate Director for Data Systems JAMES T. BAIRD, JR., Ph.D., Associate Director for International Statistics ROBERT C. HUBER, Associate Director for Managewzent MONROE G. SIRKEN, Ph.D., Associate Director for Mathematical Statistics PETER L. HURLEY, Associate Director for Operations JAMES M. ROBEY, Ph.D., Associate Director for Program Development PAUL E. LEAVERTON, Ph.D., Associate Director for Research ALICE HAYWOOD,, Information Officer DIVISION OF HEALTH EXAMINATION STATISTICS MICHAEL A. W. HATTWICK, M.D., Director JEAN ROEERTS, Chiej, Medical Statistics Branch ROBERT S. MURPHY, Chiej Survey Planning and Development Branch DIVISION OF OPERATIONS HENRY MILLER, ChieJ Health -Examination Field Operations Branch COOPERATION OF THE U.S. BUREAU OF THE CENSUS Under the legislation establishing the National Health Survey, the Public Health Service is authorized to use, insofar as possible, the sesw?icesor facilities of other Federal, State, or private agencies. In accordance with specifications established by the National Center for Health Statis- tics, the U.S. Bureau of the Census participated in the design and selection of the sample and carried out the household interview stage of :the data collection and certain parts of the statis- tical processing. -
Acne Keloidalis Nuchae
Dermatologic Therapy, Vol. 20, 2007, 128–132 Copyright © Blackwell Publishing, Inc., 2007 Printed in the United States · All rights reserved DERMATOLOGIC THERAPY ISSN 1396-0296 Blackwell Publishing Inc Acne keloidalis nuchae Acne keloidalis nuchae, also known as folliculitis its antimicrobial and antiinflammatory effect), nuchae, is a chronic scarring folliculitis charac- and a series of intralesional steroids (40 mg/cc of terized by fibrotic papules and nodules of the existing keloids). Education is the key to preven- nape of the neck and the occiput. It particularly tion. I discourage high-collared shirts, short hair- affects young men of African descent and rarely cuts, and close shaving or cutting the hair along occurs in women; in either case its occurrence the posterior hairline. In the long-term, patients has a significant impact on the patient’s quality benefit from laser hair removal using diode or of life. We’ve asked our experts to share their expe- Nd:YAG, which helps avoid disease progression. rience in helping patients with this cosmetically Early treatment decreases the morbidity that can disfiguring disorder. be associated with late-stage disease. Question Dr. Vause: I treat early acne keloidalis nuchae by instructing patients to wash the skin frequently Please describe your approach to the treatment of with a mild keratolytic like tar or an alpha hydroxy patients with early (less than 20 papules, pustules acid cleanser. Patients are instructed to apply and 1–2 < 2 cm nuchae keloids) acne keloidalis topical clindamycin with steroid in the morning nuchae. (1–3) and retinoid at bedtime. Dr. Brauner: An option is to treat all patients with Response chlorhexadine cleanser as a daily shampoo and minocycline 100 mg daily b.i.d.